Drug Trial Radar · NCT00110448
Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial
Last checked: Nov 20, 2026Latest source record: Nov 2, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,539
Actual
Start
Dec 2002
Primary completion
Apr 2008
Study completion Apr 2008
Sponsor
- Lead sponsor
- Kumamoto UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 10, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 30 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the effects of low-dose aspirin for the primary prevention of vascular events in patients with type 2 diabetes in Japan.
Conditions
- Coronary Disease
- Arteriosclerosis
- Diabetes Mellitus, Type 2
Interventions
AspirinDrug
Aspirin 81 mg or 100 mg per day
No aspirinDrug
No aspirin use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cardiovascular eventsTime frame: five years (median)
- Cerebral vascular eventsTime frame: five years (median)
- Aortic and peripheral vascular events, which needs internal medicine and/or surgical medical treatmentTime frame: five years (median)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
Kumamoto, Kumamoto, Japan
First Department of Internal Medicine, Nara Medical University
Kashihara, Nara, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.